DETER is a scientifically based approach to establishing the abuse-deterrence profile of a particular prescription opioid by measuring its abuse potential along three dimensions. Using real-time data from a network of substance abuse clinics across the U.S., DETER provides a dynamic measurement of the rates of abuse and illicit routes of administration for a specific opioid in comparison with other prescription opioid products. It also allows for the scientific assessment of a drug’s attractiveness to populations of abusers over time, as well as the monitoring of emerging strategies for defeating its abuse-deterrent properties.
DETER is an innovative approach to measuring abuse deterrence, and can provide pharmaceutical companies and regulatory agencies with empirical pre- and post-launch indicators of a drug's effectiveness for limiting abuse and its consequences.
Combining DETER with its complement, NAVIPPROTM, a turnkey risk management solution for companies that develop and market prescription opioids, offers a comprehensive risk management and abuse deterrence strategy.
DETER is a proprietary offering of Inflexxion, Inc., a privately held company that creates behavioral health solutions for prevention, education, and disease management using engaging interactive multimedia and Internet technologies. Inflexxion’s pharmaceutical risk management offerings include custom tools, products, and services to support the risk management initiatives of companies that research, manufacture, and market opioid pain medications and other therapeutic agents with potential abuse problems.
For a web-based presentation on DETER, please contact us.